These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 18677560)
1. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer. Abu-Khalaf MM; Harris L Breast Cancer Res Treat; 2009 Apr; 114(3):513-5. PubMed ID: 18677560 [No Abstract] [Full Text] [Related]
2. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147 [TBL] [Abstract][Full Text] [Related]
3. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC; Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582 [TBL] [Abstract][Full Text] [Related]
4. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer: what's HER-2/neu got to do with it? Lenahan C; Dennis C; Isakovich NV; Pories SE Curr Surg; 2005; 62(5):459-64. PubMed ID: 16125599 [No Abstract] [Full Text] [Related]
6. The prognostic and predictive values of ECD-HER-2. Hait WN Clin Cancer Res; 2001 Sep; 7(9):2601-4. PubMed ID: 11555568 [TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561 [TBL] [Abstract][Full Text] [Related]
8. [An investigation of extracellular HER-2/NEU domain level in blood serum from breast cancer patients]. Korytova LI; Masliukova EA; Ovchinnikov IV; Filipenko MO; Korytov OV; Kudaĭbergenova AG Vopr Onkol; 2010; 56(1):62-5. PubMed ID: 20361618 [TBL] [Abstract][Full Text] [Related]
9. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Pichon MF; Hacene K; Guepratte S; Neumann R Clin Lab; 2004; 50(3-4):163-70. PubMed ID: 15074470 [TBL] [Abstract][Full Text] [Related]
10. Is circulating HER-2 more than just a tumor marker? Baselga J Clin Cancer Res; 2001 Sep; 7(9):2605-7. PubMed ID: 11555569 [No Abstract] [Full Text] [Related]
11. Concentration of serum HER-2/neu as a prognostic factor in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). Purwanto I; Kurnianda J; Hariadi KW; Harijadi ; Aryandono T; Setiaji K; Harianti MS; Haryana SM Acta Med Indones; 2011 Jan; 43(1):23-8. PubMed ID: 21339542 [TBL] [Abstract][Full Text] [Related]
12. Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer? Esteva FJ Oncologist; 2008 Apr; 13(4):370-2. PubMed ID: 18448550 [No Abstract] [Full Text] [Related]
13. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumor markers in breast cancer. Tondini C; Hayes DF; Kufe DW Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493 [TBL] [Abstract][Full Text] [Related]
15. [Serum HER-2 determination using a centauer HER-2/neu kit (CLIA method) in metastatic breast cancer]. Kan N; Yoshikawa S Gan To Kagaku Ryoho; 2009 May; 36(5):779-83. PubMed ID: 19461177 [TBL] [Abstract][Full Text] [Related]
16. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma. Schulze G Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339 [TBL] [Abstract][Full Text] [Related]
17. Serum tumor markers in patients with breast cancer. Lumachi F; Basso SM Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325 [TBL] [Abstract][Full Text] [Related]
18. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A J BUON; 2008; 13(3):409-13. PubMed ID: 18979558 [TBL] [Abstract][Full Text] [Related]
19. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells in breast cancer. Ignatiadis M; Georgoulias V; Mavroudis D Curr Opin Obstet Gynecol; 2008 Feb; 20(1):55-60. PubMed ID: 18197007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]